Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.86 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | IL1B | P01584 | 1/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639152 | 1.00 | CRBN (0.86) | CRBNIKZF2DDB1CSNK1A1BRD4 | |
| SCHEMBL29440001 | 0.93 | CRBN (1.00) | CRBNIKZF2DDB1CSNK1A1BRD4 | |
| SCHEMBL501751 | 0.93 | CRBN (1.00) | CRBNIKZF2DDB1CSNK1A1BRD4 | |
| SCHEMBL20234431 | 0.93 | CRBN (1.00) | CRBNIKZF2DDB1CSNK1A1BRD4 | |
| SCHEMBL30930592 | 0.85 | CRBN (0.63) | CRBNIKZF2DDB1CSNK1A1 | |
| SCHEMBL18270971 | 0.85 | CRBN (0.63) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL19611952 | 0.85 | CRBN (0.63) | CRBNIKZF2DDB1IKZF3 | |
| SCHEMBL19611954 | 0.85 | CRBN (0.63) | CRBNIKZF2DDB1IKZF3 | |
| SCHEMBL20231070 | 0.83 | CRBN (0.82) | CRBNIKZF2DDB1CSNK1A1BRD4 | |
| SCHEMBL30405557 | 0.82 | CRBN (0.66) | CRBNIKZF2DDB1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298004-B1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX INC (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10669260-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10562917-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190276474-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-9938302-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180065952-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017201069-A1 | OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS | BIOTHERYX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-9822098-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160362397-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2016191178-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065952-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, APC | CRBN 548/4885IKZF2 9/4885DDB1 2732/4885 |
| US-10669260-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | IKZF3, IKZF1, APC | CRBN 548/4885IKZF2 9/4885DDB1 2732/4885 |
| US-10562917-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF2 44/4885DDB1 2485/4885 |
| US-20160362397-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, APC | CRBN 548/4885IKZF2 9/4885DDB1 2732/4885 |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF2 44/4885DDB1 2485/4885 |
| US-20190276474-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF2 44/4885DDB1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.